UnlockBeiGene's SVP sells shares worth nearly $285k
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BeiGene Ltd (BGNE)
NASDAQ
Currency in USD
Disclaimer
241.89
-4.15(-1.69%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
239.87
247.50
52 wk Range
126.97
248.16
BGNE Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
BeiGene Ltd stock price live, this page displays NASDAQ BGNE stock exchange data. View the BGNE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BeiGene Ltd real time stock price chart below.
What Is the BeiGene Ltd Stock Price Today?
The BeiGene Ltd stock price today is 241.89.
What Is the Stock Symbol for BeiGene Ltd?
The stock symbol for BeiGene Ltd is "BGNE."
What Stock Exchange Does BeiGene Ltd Trade On?
BeiGene Ltd is listed and trades on the NASDAQ stock exchange.
Is BeiGene Ltd a Good Stock to Buy?
Determining whether BeiGene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BGNE quote. (ISIN: US07725L1026)
What Is the BeiGene Ltd Stock Price Today?
The BeiGene Ltd stock price today is 241.89.
What Is the Stock Symbol for BeiGene Ltd?
The stock symbol for BeiGene Ltd is "BGNE."
What Stock Exchange Does BeiGene Ltd Trade On?
BeiGene Ltd is listed and trades on the NASDAQ stock exchange.
Is BeiGene Ltd a Good Stock to Buy?
Determining whether BeiGene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BGNE quote. (ISIN: US07725L1026)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
239.87247.50
52 wk Range
126.97248.16
BGNE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
274.14
Upside
+13.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
- BeiGene executive sells over $1.1m in company shares
- Investing.com
- BeiGene Appoints Shalini Sharp to its Board
- Investing.com
- BeiGene's SVP sells shares worth nearly $285k
- Investing.com
- BeiGene executive sells over $1.1m in company shares
- Investing.com
BeiGene ADS Company Profile
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Compare BGNE to Peers and Sector
Metrics to compare | BGNE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBGNEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −49.1x | −8.5x | −0.6x | |
PEG Ratio | −0.72 | −0.02 | 0.00 | |
Price/Book | 7.6x | 4.3x | 2.6x | |
Price / LTM Sales | 8.3x | 14.1x | 3.2x | |
Upside (Analyst Target) | 15.6% | 254.9% | 44.4% | |
Fair Value Upside | Unlock | 29.4% | 6.2% | Unlock |
FAQ
What Is the BeiGene ADS (BGNE) Stock Price Today?
The BeiGene ADS stock price today is 241.89.
What Stock Exchange Does BeiGene ADS Trade On?
BeiGene ADS is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for BeiGene ADS?
The stock symbol for BeiGene ADS is "BGNE."
What Is the BeiGene ADS Market Cap?
As of today, BeiGene ADS market cap is 26.19B.
What is BeiGene ADS Earnings Per Share?
The BeiGene ADS EPS is -5.01.
What Is the Next BeiGene ADS Earnings Date?
BeiGene ADS will release its next earnings report on 06 Nov 2024.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.